Bristol/Sanofi Receive FTC Subpoena Over Failed Plavix Settlement With Apotex
This article was originally published in The Pink Sheet Daily
Both firms say they will comply with investigation seeking documents.
You may also be interested in...
With preliminary injunction rulings weighing in Sanofi/Bristol's favor, Apotex's defense will need to make a strong case that clopidogrel patents are invalid.
PhRMA is among the parties scheduled to testify at the panel next week, which could coincide with the reintroduction of Sen. Kohl’s bill to curb settlements.
Bristol estimates that “at risk” launch of generic clopidogrel impacted U.S. pharma sales by $525 mil. to $600 mil.